Community Practice Connections™: Let's Get “Real”: Minimizing Allograft Rejection in Renal Transplantation – Applying the Evidence to Real-World Scenarios

Released On
September 10, 2021

Expires On
September 10, 2022

Media Type

Completion Time
60 minutes

Pharmacy, Nephrology, Primary Care, Transplant Medicine, Immunology

Pharmacology, Immunology, Organ transplantation

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


This activity is supported by an educational grant from Sanofi US

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for transplant specialists, transplant surgeons, and nephrologists. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment and management of patients who receive renal grafts will also be invited to participate.

Program Overview

Although individuals who receive kidney transplants have high rates of survival—both for themselves and their grafts—at 1 year, clinicians continue to face challenges in preventing rejection and maintaining these outcomes over the long term.

This Community Practice Connections™ program provides an in-depth review of some key highlights from a live satellite symposium presented during the American Transplant Congress, which was held in June 2021. This unique and engaging multimedia activity is ideal for the community-based clinician. This program both focuses on the practical aspects of managing kidney transplant candidates and recipients and puts recent clinical trial data into clinical context. It is designed to provide pertinent clinical information for those who did not attend the live event and to help reinforce learnings for those who did.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review mechanisms of renal transplant rejection that may offer targets for therapy
  • Develop management plans using current and emerging therapies for desensitization of patients undergoing renal transplantation
  • Apply strategies to improve adherence to treatment regimens following renal transplantation



Rita R. Alloway, PharmD

Research Professor
University of Cincinnati College of Medicine
Cincinnati, OH


Daniel Brennan, MD

Medical Director, Comprehensive Transplant Center
Professor of Medicine
Johns Hopkins Medicine
Baltimore, MD


E. Steve Woodle, MD, FACS

Director, Solid Organ Transplantation
UC Health
William A. Altemeier Chair in Surgery
Professor of Surgery
Director of Israel Penn International Transplant Tumor Registry
University of Cincinnati College of Medicine
Cincinnati, OH

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Rita R. Alloway, PharmD

  • Grant Research Support: Novartis Pharmaceuticals, Amgen, GlaxoSmithKline, Sanofi, Bristol Myers Squibb, Hookipa Pharma, Veloxis Pharmaceuticals, Nobelpharma, AlloVir
  • Consultant: Veloxis Pharmaceuticals
  • Speakers’ Bureau: Veloxis Pharmaceuticals, Sanofi

Daniel Brennan, MD

  • Grant Research Support: AlloVir, Amplyx Pharmaceuticals, CareDx, Natera
  • Consultant: CareDx, Hansa Biopharma, Medeor Therapeutics, Sanofi, Veloxis Pharmaceuticals
  • Speakers’ Bureau: CareDx, Veloxis Pharmaceuticals

E. Steve Woodle, MD, FACS

  • Grant Research Support: Novartis Pharmaceuticals, Amgen, Bristol Myers Squibb, Veloxis Pharmaceuticals
  • Consultant: Novartis Pharmaceuticals
  • Speakers’ Bureau: Sanofi

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.